Highlights in breast cancer from the 2014 American Society of Clinical Oncology® annual meeting.

Highlights from the Gynecologic Oncology Track at the 2017 Annual Meeting of the American Society of Clinical Oncology

The American Society of Clinical Oncology (ASCO) 2017 Annual Meeting was held again at the McCormick Convention Center in Chicago, IL, USA. Over 37,500 international physicians, nurses, researchers, and exhibitors descended on the Windy City from June 2nd, 2017 through June 6th, 2017. This year's ASCO presidential theme, “Making a Difference in Cancer Care with You,” embodied the principle of t...

A golden anniversary: highlights of the 50th annual meeting of the American Society of Clinical Oncology

The 50th Annual Meeting of the American Society of Clinical Oncology showed a shift in the culture of cancer research, moving towards multidisciplinary, integrated, and patient-centric work. Hormone-sensitive cancers were particularly highlighted at this meeting, and impressive strides were made in the previously underserved areas of the lung and thyroid cancer. Interestingly, immunotherapy was...

Highlights in metastatic colorectal cancer from the 2012 American Society Of Clinical Oncology Annual Meeting.

Modifiable Risk Factors Affecting Outcomes: The Truth About Obesity

The American Society of Clinical Oncology (ASCO) held its annual meeting this past June. As usual, participants had the opportunity to learn and discuss the latest in oncology research findings. Although I didn’t attend the meeting in person, I noted the daily reports with interest. I was particularly appalled by the results of a study examining 80,000 patients in early breast cancer trials and...

American society of clinical oncology, 45th annual meeting.

The 46th Annual Meeting of the American Society of Clinical Oncology, held in Chicago, included topics covering new therapeutic developments in the field of oncology. This conference report highlights selected presentations on novel therapies for cancers including glioblastoma, breast cancer, myeloma, NSCLC and solid tumors. Investigational drugs discussed include rindopepimut and PF-299804 (bo...

Eisai Oncology to Present New Research on Product Portfolio, Pipeline at Asco Annual Meeting

PIPELINE AT ASCO ANNUAL MEETING Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, “Eisai”) announced today that 19 abstracts highlighting new study results on thyroid cancer, acute myeloid leukemia, metastatic breast cancer, ovarian cancer and other cancers will be presented during the 47 Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Ch...